Numerai GP LLC Sells 9,111 Shares of Haemonetics Co. (NYSE:HAE)

Numerai GP LLC lessened its holdings in Haemonetics Co. (NYSE:HAE - Free Report) by 60.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,968 shares of the medical instruments supplier's stock after selling 9,111 shares during the quarter. Numerai GP LLC's holdings in Haemonetics were worth $466,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in HAE. TD Waterhouse Canada Inc. acquired a new position in Haemonetics in the 4th quarter worth $25,000. Covestor Ltd lifted its stake in shares of Haemonetics by 146.8% in the fourth quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier's stock worth $58,000 after acquiring an additional 439 shares in the last quarter. Whittier Trust Co. purchased a new position in Haemonetics in the fourth quarter valued at about $62,000. Parkside Financial Bank & Trust raised its position in shares of Haemonetics by 25.6% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock valued at $92,000 after purchasing an additional 240 shares in the last quarter. Finally, AlphaQuest LLC boosted its holdings in shares of Haemonetics by 36,520.0% in the fourth quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier's stock valued at $143,000 after acquiring an additional 1,826 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company's stock.

Haemonetics Stock Performance

Shares of NYSE HAE traded down $0.92 during mid-day trading on Monday, reaching $69.39. 344,207 shares of the company's stock were exchanged, compared to its average volume of 699,066. Haemonetics Co. has a 52 week low of $55.30 and a 52 week high of $95.53. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.97 and a quick ratio of 2.55. The firm has a 50-day moving average price of $62.92 and a two-hundred day moving average price of $71.21. The firm has a market capitalization of $3.49 billion, a price-to-earnings ratio of 27.32, a price-to-earnings-growth ratio of 1.11 and a beta of 0.32.

Haemonetics (NYSE:HAE - Get Free Report) last issued its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share for the quarter, topping analysts' consensus estimates of $1.22 by $0.02. The firm had revenue of $330.60 million during the quarter, compared to analyst estimates of $329.38 million. Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. The company's quarterly revenue was down 3.5% on a year-over-year basis. During the same quarter last year, the business earned $0.90 earnings per share. Analysts predict that Haemonetics Co. will post 4.55 EPS for the current year.

Wall Street Analyst Weigh In

HAE has been the topic of several recent analyst reports. Raymond James reiterated a "strong-buy" rating and issued a $105.00 target price (down previously from $115.00) on shares of Haemonetics in a report on Friday, May 9th. Bank of America cut Haemonetics from a "neutral" rating to an "underperform" rating and decreased their target price for the company from $95.00 to $68.00 in a research note on Friday, February 7th. Needham & Company LLC lowered their price target on Haemonetics from $104.00 to $84.00 and set a "buy" rating for the company in a report on Thursday, May 8th. StockNews.com cut Haemonetics from a "buy" rating to a "hold" rating in a research note on Tuesday, May 13th. Finally, JMP Securities lowered their target price on Haemonetics from $125.00 to $100.00 and set a "market outperform" rating for the company in a research note on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $97.89.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.